All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Improving outcomes for people of color with chronic plaque psoriasis including scalp involvement
with Paolo Gisondi, Andrew Alexis, and Mona Shahriari
Thursday, February 6, 2025
16:00-17:00 GMT
This independent educational activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Guselkumab in patients with PsA and TNFi-IR: Results from the phase IIIb COSMOS trial
By Ella Dixon
|
The phase IIIb COSMOS trial evaluated the efficacy of guselkumab, an interleukin-23 inhibitor, in patients with active PsA and TNFi-IR. Responses, including PROs, were measured at Week 24 and Week 48. Patients who were originally randomized to placebo were switched to guselkumab at Week 16 and Week 24, with a total of 285 patients randomized; 189 assigned to guselkumab and 96 assigned to placebo. |
| Key learnings |
| At Week 24, guselkumab improved ACR 20 (50% vs 28%; odds ratio [OR], 2.6; 95% confidence interval [CI], 1.5–4.6) and ACR 50 responses (23% vs 8%; OR, 3.2; 95% CI, 1.4–8.3) compared with placebo; improvements were sustained through Week 48. |
| Guselkumab vs placebo resulted in higher rates of PASI 90 (58% vs 11%) and PASI 100 (35% vs 8%), enthesitis (47% vs 23%) and dactylitis resolution (57% vs 36%), and patient-reported FACIT-Fatigue response (49% vs 26%) and HAQ-DI score (42% vs 24%). |
| The benefits of achieving ACR 20 were consistent across patient subgroups, regardless of demographics, disease severity, or prior treatments (including the number of prior TNFi therapies). Responses to guselkumab increased or were maintained through Week 48, illustrating its long-term effectiveness. |
| Guselkumab provides a reliable treatment option for diverse subgroups of patients with PsA and TNFi-IR, addressing an unmet need for effective, durable therapies in this patient population. |
Abbreviations: ACR, American College of Rheumatology response; FACIT, Functional Assessment of Chronic Illness Therapy; HAQ-DI, Health Assessment Questionnaire–Disability Index; IL, interleukin; PASI, Psoriasis Area and Severity Index; PRO, patient-reported outcomes; PsA, psoriatic arthritis; TNFi-IR, inadequate response or intolerance to prior tumour necrosis factor inhibitor.
- McInnes IB, Sewerin P, Sharaf M ,et al. Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial. RMD Open. 2024; 10(4):e004494. DOI: 10.1136/rmdopen-2024-004494
More about...
Your opinion matters
13 votes - 22 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox